New Options (or not) for Treatment of Idiopathic Intracranial Hypertension

Curr Neurol Neurosci Rep. 2022 Apr;22(4):257-264. doi: 10.1007/s11910-022-01188-5. Epub 2022 Mar 25.

Abstract

Purpose of review: Idiopathic intracranial hypertension (IIH) is a disorder primarily affecting obese women of childbearing age and, if left untreated, can lead to irreversible vision loss. No consensus exists on the best management strategy for IIH. Weight loss is advocated and few useful medical options exist. There is an unmet need to discover new treatment options for this increasingly prevalent condition. This article reviews the recent advances and research on the treatment of IIH.

Recent findings: Venous sinus stenting (VSS) is now performed in many experienced centers, and there is growing interest in bariatric surgery as a treatment modality. Newly approved anti-obesity drugs are showing effectiveness in weight loss, and novel targeted disease-modifying IIH therapies are being explored. Further evaluation of these novel therapeutic strategies as well as studies exploring the use of anti-obesity drugs in IIH is needed. While VSS is gaining popularity due to its efficacy and low complication rate, there is insufficient evidence to support any surgical procedure over another. Bariatric surgery is appealing for patients with non-sight-threatening IIH and needs to be further explored.

Keywords: 11β-hydroxysteroid dehydrogenase type 1; Carbonic anhydrase inhibitor; Glucagon-like peptide 1 receptor agonist; Idiopathic intracranial hypertension; Venous sinus stenting.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents*
  • Female
  • Humans
  • Obesity / complications
  • Obesity / surgery
  • Pseudotumor Cerebri* / therapy
  • Stents
  • Weight Loss

Substances

  • Anti-Obesity Agents